{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:92829",
      "entity_text" : "Gy",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0649" ],
      "Cellular_component" : [ "go:GO:0009986" ],
      "Organ" : [ "uberon:UBERON:0000105" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000034" ]
    }
  },
  "verbose_text" : "Interestingly, we were able to demonstrate an influence of concomitant conventional drug regiments like chemotherapy and/or proteasome inhibitors on the expression of the CXCR4 cell surface receptor expression : Visually, in patient # 6, intermittent therapy with one cycle of bortezomib, bendamustine, dexamethasone as well as dexamethasone, carmustine, etoposide and cytosine, respectively, significantly reduced CXCR4 expression during pre-therapeutic dosimetry as compared to diagnostic [68 Ga] Pentixafor-PET/CT -a finding which could already be observed in small cell lung cancer 12 - partly explaining the low tumor doses achieved in this patient (< = 4 Gy).",
  "reading_complete" : "2020-08-02T08:32:24Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:30:54Z",
  "trigger" : "expression",
  "evidence" : [ "expression: Visually, in patient #6, intermittent therapy with one cycle of bortezomib, bendamustine, dexamethasone as well as dexamethasone, carmustine, etoposide and cytosine, respectively, significantly reduced CXCR4 expression during pre-therapeutic dosimetry as compared to diagnostic [ 68 Ga]Pentixafor-PET/CT -a finding which could already be observed in small cell lung cancer  12 - partly explaining the low tumor doses achieved in this patient (<=4 Gy" ],
  "pmc_id" : "5436514",
  "score" : 0
}